Please try another search
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Name | Age | Since | Title |
---|---|---|---|
Robertson H. Gilliland | 44 | 2014 | Independent Director |
Giovanni Addolorato | - | 2018 | Chairperson of Scientific Advisory Board |
J. Kermit Anderson | 74 | 2015 | Independent Director |
Tony Goodman | 60 | 2017 | COO & Director |
Sebastian Mueller | - | 2019 | Member of Scientific Advisory Board |
James W. Newman | 81 | 2014 | Independent Director |
Kevin Schuyler | 55 | 2016 | Chairman & Lead Independent Director |
Cary John Claiborne | 63 | 2021 | CEO, President & Director |
Tomáš Zima | - | 2019 | Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review